Carole P.
- Country
- France
- Department
- Oncologie
Research Overview
- Evaluation of Reduced Duration of Adjuvant Endocrine Therapy with Exemestane, Anastrozole, and Letrozole in Postmenopausal Women with Low-Risk HR+ HER2- Breast Cancer
- Evaluation of Therapeutic De-escalation in HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination in Patients with Controlled Disease
- Phase 3 Randomized Study of Zanidatamab Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in Metastatic HER2-Positive Breast Cancer
Data & Insights
Has run more than one trial at 27 of 134 partner sites.
Specializations
Breast cancer and hormone-driven disease
Carole PFLUIO is involved in clinical research across a broad spectrum of breast cancer, with particular attention to HER2-positive, HER2-negative, hormone receptor-positive, and triple-negative breast cancer. Her activity also extends to early-stage, locally advanced, metastatic, and recurrent settings, including biomarker-defined disease.
- HER2-positive and HER2-low breast cancer
- ER-positive, HER2-negative metastatic breast cancer
- Triple-negative and high-risk early breast cancer
- Biomarker-guided endocrine and targeted therapy
Her research interests include treatment strategies linked to BRCA, HRR, ESR1, and ctDNA status, as well as endocrine resistance and maintenance approaches in advanced disease.
Genitourinary oncology
Her clinical trial portfolio includes major work in prostate cancer, renal cell carcinoma, and urothelial carcinoma, covering both localized and metastatic disease. The research landscape also includes treatment-resistant and biomarker-selected populations.
- Metastatic castration-resistant prostate cancer
- Metastatic renal cell carcinoma
- Advanced urothelial carcinoma
- PSMA- and molecularly selected prostate cancer
She is also engaged in studies involving PARP inhibition, immune checkpoint therapy, and targeted combinations for genitourinary malignancies.
Gastrointestinal and hepatobiliary malignancies
Carole PFLUIO participates in research on gastric cancer, colorectal cancer, biliary tract carcinoma, hepatocellular carcinoma, and esophageal cancer. Her trial activity spans both advanced and resected disease, with interest in difficult-to-treat upper and lower gastrointestinal tumors.
- Gastric and gastroesophageal junction cancer
- Colorectal cancer and rectal adenocarcinoma
- Biliary tract carcinoma and cholangiocarcinoma
- Hepatocellular carcinoma
Her work also includes molecularly defined gastrointestinal tumors, such as FGFR-altered disease and MSI/dMMR cancers.
Thoracic, head and neck, and gynecologic cancers
Her research covers non-small cell lung cancer, small-cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, and ovarian cancer. These studies include locally advanced, metastatic, recurrent, and maintenance treatment settings.
- Non-small cell and small-cell lung cancer
- Head and neck squamous cell carcinoma
- Cervical cancer and HPV-related malignancies
- Ovarian, fallopian tube, and primary peritoneal cancer
Her therapeutic focus includes immunotherapy, antibody-drug conjugates, and biomarker-driven approaches in HPV-16-positive and other molecularly selected tumors.
Hematologic malignancies and rare solid tumors
Carole PFLUIO is also active in trials involving acute myeloid leukemia, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and multiple myeloma. Her portfolio further includes rare cancers such as soft tissue sarcoma, osteosarcoma, adrenocortical carcinoma, and gastrointestinal stromal tumor.
- Acute and chronic leukemias
- Lymphoma and plasma cell disorders
- Soft tissue and bone sarcomas
- Rare endocrine and mesenchymal tumors
Her clinical interests include bispecific antibodies, cell-based therapies, and targeted treatment options for uncommon and high-risk malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.